Is Artemis Medicare overvalued or undervalued?

As of 10 October 2025, the valuation grade for Artemis Medicare has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered overvalued based on its high PE ratio of 38.11, a Price to Book Value of 3.97, and an EV to EBITDA of 20.50. In comparison to its peers, Artemis Medicare's PE ratio is significantly lower than that of Max Healthcare, which stands at 93.27, but higher than Apollo Hospitals at 70.15, suggesting that while it is more reasonably priced than the most expensive competitor, it still carries a premium.
The PEG ratio of 0.71 indicates that Artemis Medicare may have growth potential relative to its price, yet its current valuation metrics suggest that it is trading at a higher multiple than what might be justified by its earnings growth. The company has underperformed the Sensex year-to-date with a return of -23.77% compared to the index's 5.58%, reinforcing the notion that the stock may be overvalued in the current market context.